中国6省市急性乙型病毒性肝炎住院病例诊断与报告一致性分析

目的 了解乙型病毒性肝炎（乙肝）监测点报告的急性乙肝住院病例的基本特征,分析报告的急性乙肝病例与临床医生诊断的一致性。方法 从全国法定传染病报告系统（NNDRS）中获得急性乙肝病例信息,通过查询医院信息系统（Hospital Information System）了解急性乙肝的基本情况,记录本次就诊住院的临床诊断,分析临床医生的急性乙肝诊断与NNDRS中的报告类型相一致的比例。结果 本次研究对象共179例,均为2015-2016年NNDRS中报告的急性乙肝病例,其中HBsAg阳性时间6个月由阴性转为阳性者占2.79%（5/179）,HBsAg阳性持续时间≥6个月者占32.40%（58/179）,本次为第一次检测HBsAg或时间不详的占64.80%（116/179）;有乙肝病史的占33.52%（60/179）,有甲、丙肝病史的占1.12%（2/179）,无肝炎病史的占41.34%（74/179）,肝炎病史不详的占24.02%（43/179）;有肝炎症状和体征的占79.89%（143/179）,无肝炎症状和体征的占20.11%（36/179）。179例NNDRS报告的急性乙肝病例中,临床医生诊断为急性乙肝67例,非急性乙肝112例,急性乙肝一致率为37.43%（67/179）。不一致的病例共计112例,以诊断为慢性乙肝（49.11%,55/112）和乙肝后肝硬化（16.07%,18/112）为主。结论 NNDRS中报告的急性乙肝住院病例报告类型与临床医生的急性乙肝诊断类型一致性较差。临床医生在保证诊断准确性的前提下,应按照临床诊断分类进行网络报告,使NNDRS中乙肝的分类类型与临床医生的分类诊断相一致。     

杭州市病毒性肝炎分布特征及其防制对策的研究

本文报道了应用前瞻性调查方法，对1987年杭州市城区、水网区、半山区和山区确诊的急性病毒性肝炎1248例血清病原学分型及流行病学调查，结果甲肝占69．71％，乙肝占7．13％，非甲非乙肝占21．96％，甲、乙肝混合感染占1．20％。城、乡均以甲肝占首位，非甲非乙肝次之。甲肝流行的主要危险因素有：①家庭使用马桶、坐坑；②接触肝炎病人；③喝生水。非甲非乙肝以肠道外传播型为主，看牙病（拔牙）是主要危险因素，在此基础上提出相应对策。     

Hepatitis C in Poland in 2001

Hepatitis C is a notifiable disease in Poland since 1997. The increasing trend in incidence over the last four years may be explained by continuous improvement of diagnosis and notification. In the year 2001, for the first time since 1997, a number of cases and an incidence of hepatitis C was lower than in preceding years. The total number of 1953 acute and chronic hepatitis C cases has been reported in 2001. Incidence per 100,000 inhabitants was 5.05. The differences in hepatitis C incidence in regard to gender, region and age have been observed. The incidence in urban regions was higher than in rural; 6.49/100,000 and 2.74/100,000, respectively. The incidence among men was higher than in women; 5.87/100,000 and 4.28/100,000, respectively. Coinfection with hepatitis B has been observed in 5.84% of hepatitis C cases.     

2012-2018年江西省急性乙型病毒性肝炎流行病学特征分析

目的 分析2012-2018年江西省急性乙型病毒性肝炎(乙肝)的流行病学特征,为评价乙肝免疫策略效果和制定防控措施提供依据。方法 从中国疾病预防控制信息系统(NNDRS)中下载江西省2012-2018年急性乙肝疫情资料,运用流行病学方法对其流行特征进行分析。结果 2012-2018年江西省共报告急性乙肝病例10409例,年平均发病率为3.27/10万,报告发病数和发病率均呈逐年下降趋势;各设区市均有急性乙肝病例报告,报告发病率最高的设区市为萍乡市(13.90/10万);报告发病率最高的年龄组为25~岁组(6.58/10万),最低的为5~岁组(0.18/10万);15~45岁病例6524例(62.68%),<15岁病例283例(2.72%);男性发病率高于女性,男女性别比为2.38〖DK〗∶1;病例以农民最多(6347例,占60.98%),其次是家务及待业人群(1234例,占11.86%)。结论 2012-2018年江西省急性乙肝病例以男性、农民、15~45岁人群为主,报告发病数和发病率均逐年降低,地区间发病水平及其变化趋势有差异。     

Update on hepatitis B vaccination in Italy 10 years after its implementation

Since the beginning of the Italian program of immunization against hepatitis B, vaccine has been given to more than 9 million children, with an outstanding record of safety and efficacy. The coverage rate is globally around 94%, with differences between Northern and Southern regions, the latter having the lower acceptance rate. According to the National Surveillance System (SEIEVA), the incidence of acute hepatitis B per10(5) inhabitants declined from 5.4 in 1990 to 2.9 in 1998. The reduction was even greater among 15-24-year-old individuals, where the incidence rate per 10(5) decreased from 17.3 to 4.2 in the same period. In parallel with the decline of hepatitis B, Delta hepatitis has also dropped significantly. We expect that by the year 2003 (12 years after the beginning of the program) this vaccination strategy will have led to the protection of all Italians aged 0-24 years, who are those at the higher risk for acquiring hepatitis B virus (HBV) and for developing the chronic carrier state.     

检测唾液IgM抗-HAV诊断甲型肝炎的研究

本文采用检测唾液IgM抗-HAV来诊断甲型病毒性肝炎(甲肝)进行了研究。结果表明,IgM抗-HAV能可靠地在血清学证实的58例急性甲肝和9例甲乙混合感染的患者唾液中检出,而不能在非甲肝患者其中包括84例急性乙肝和30例非甲非乙肝及10例健康人唾液中检出。证明采用唾液标本来诊断甲肝是特异的。唾液比血清更易获得,这就为今后甲肝的诊断和流行病学调查提供了更有利的条件。     

散发性急性病毒性肝炎血清学分型的研究

为研究非甲型肝炎流行季节散发性急性病毒性肝炎的病原学构成，采用ＥＩＡ法，对２４８份急性病毒性肝炎患者血清，进行了血清学分型检测。结果显示，非甲型肝炎流行期散发病例仍以甲型肝炎为主，占６１．３％，以青少年为主，随年龄增长患病率降低。乙型肝炎居第二位占２６．２％，以中老年为主，随年龄增长患病率增高。丙型肝炎占９．９％，戊型肝炎占２２．２％，各年龄组间变化不明显。丁型肝炎患病率为１２．７％，ＨＤＡｇ检出率为１２％。双重感染占１８．９％，检测指标全部阴性占０．８％。丙型和戊型肝炎的ＩｇＧ型抗体与同期献血员比较，差异有非常显著性。病例中黄疸型占６８％，甲型肝炎占黄疸总数的８６．８％。乙型肝炎患者合并或联合感染丁型肝炎，病情易慢性化。     

Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy

An epidemic outbreak of HCV infection was observed in the center of nonconventional therapy, when patients with stable coronary heart disease and arteriosclerosis obliterans were treated. They received drop infusions with chelate therapy with unknown medicine. We diagnosed acute hepatitis C in 15 patients (mean age 61). All were positive for HCV RNA, had known exposure to HCV within the preceding 3 months and elevated serum ALT value 2-10 ULN. 12 out of 15 patients had documented seroconversion to anti-HCV. In 6 patients liver biopsy was performed. Acute viral hepatitis was diagnosed in 4 cases (of mild activity in 2 cases and of moderate activity in the other two cases). In two remaining cases histology required differentiation diagnosis (one with non alcoholic steatohepatitis and one with exacerbation of chronic hepatitis). Different forms of hepatocyte degeneration and steatosis were observed in all cases. Considering the possibility to chronicity we decided to treat 10 patients, while remaining 5 had contraindications to interferon therapy. There was no control group. Patients were treated with pegylated alfa 2b interferon 1.5 mcg/kg/week and ribavirin 1000-1200 mg/d, for 12 weeks. Side effects appear minimal. In no case therapy was interrupted. Sustained viral response (SVR) and normalization of ALT were observed in 6 out of 10 treated patients (1 with jaundice and 5 asymptomatic). Two untreated subjects had spontaneous recovery. We found that administration of pegylated interferon alfa-2b and ribavirin 1-6 months after the appearance of jaundice or significant elevation of ALT activity could prevent progression to chronic infection. This therapy appears to be effective and safe in asymptomatic infection and among others in adult patients with stable coronary heart disease. Our results confirmed the previous observations mentioned by others that treatment of acute hepatitis C with pegylated interferon and ribavirin may lead to cure.     

Hepatitis B in children in Italy: Incidence and risk factors

The objectives of the present report were to give a baseline picture of hepatitis B notification incidence rates in children before the campaign of mass vaccination for newborns and adolescents (12–13 years old), and to study the role of different risk factors. Data from a specific national surveillance system of acute viral hepatitis (SEIEVA, Sistema Epidemiologico Integrato dell'Epatite Virale Acuta) were used and acute hepatitis B cases were compared to acute hepatitis A patients with the case-control study method to estimate the associations with the considered risk factors. Since the system began, one hundred and sixty-three local health departments have joined SEIEVA covering 30% of the Italian population. The incidence of acute hepatitis B notifications among 0–14 aged children was 9 per 100,000 in 1985 and 1 per 100,000 in 1990. Such decline in incidence was observed in both the North and the South of Italy. Surgical interventions, dental therapy and household contacts with a HBsAg chronic carrier were found to be associated with acute hepatitis B. The point estimate of the odds ratio was 10 for the latter risk factor. Other preventive measures in addition to vaccination are needed to control the risk of hepatitis B infection and other parenteral diseases due to surgical intervention and dental therapy.     

5 805例病毒性肝炎的病原学分析

[目的]研究上海市普陀区人群病毒性肝炎病原学的特征,制定科学的预防措施。[方法]对1990年1月~2003年12月在普陀区中心医院门诊就诊的5805例病毒性肝炎患者,进行血清病原学分型及流行病学研究。[结果]5805例中,甲、乙、丙、丁、戊型病毒性肝炎分别占21.45%、49.96%、1.19%、0.07%、3.50%,未分型者占14.26%,混合感染型占9.58%。年龄分布主要集中在20~49岁,占70.94%。甲肝病例中10~39岁者占83.53%,乙肝中20~49岁者占71.69%。男性患者3836例,女性患者1969例,男女性患者之比为1.95∶1。职业分布情况,干部1529例(26.34%),工人1565例(26.96%),学生477例(8.22%),农民414例(7.13%),其他1820例(31.35%)。每年1~3月为高发季节,分别占9.84%、10.47%和10.73%,其他月份病例数占6.58%~8.72%。1992~1994年间发病数高于其他年份。临床分型中急性黄疸型肝炎3332例(57.40%),急性无黄疸型肝炎846例(14.57%),慢性肝炎1435例(24.72%),重型肝炎52例(0.90%),肝炎肝硬化140例(2.41%)。[结论]甲型和乙型病毒性肝炎是普陀区常见的肝炎类型。急性黄疸型肝炎是主要的临床类型。注意个人卫生有助于预防甲肝和戊肝传播,接种甲肝疫苗和乙肝疫苗是有效的预防措施,肝炎疫情监测及不同对策亦应加强。     

中国2013-2020年乙型肝炎发病情况估算和病例特征分析

目的:为了解我国乙型肝炎（乙肝）病例的发病特征,为评估我国消除乙肝目标的实现情况,制定乙肝防控规划提供科学依据。方法:对2013-2020年我国高、中、低流行区的全国法定传染病报告系统（NNDRS）中报告的乙肝病例进行调查,分析报告的病例的诊断信息,通过报告信息和诊断信息对2013-2020年的乙肝病例发病情况进行估算...     

Six years of sentinel surveillance of hepatitis B in general practice in France

Despite the availability of a safe and efficacious vaccine, new cases of infection by hepatitis B virus (HBV) still occur at a substantial rate. This increases the current prevalence of chronic HBV carriers (10% of newly infected subjects) and in the long run, will raise the incidence of chronic liver disease. The surveillance of viral hepatitis commenced in December 1990 by the French sentinel network for electronic surveillance of communicable diseases. Between 1991 and 1996, a decrease in the annual incidence was observed although it was not significant (p=0.06). The mean number of cases for this period was 12 per 100,000 inhabitants. The sex ratio (M/F) was 1.6 (p<0.01) and the median age, 32 years. Heterosexual transmission was suspected in 25% of cases, homo- bisexual transmission in 10%, use of injected drugs in 19%, percutaneous exposure in 9%, and blood transfusion or hemodialysis in 6%. Although the incidence of HBV infection is decreasing, the prevalence of chronic infection will continue to rise. However, the universal hepatitis B immunisation strategy proposed by WHO will dramatically limit the expansion of the population of chronically infected subjects if high coverage is achieved rapidly.     

Epidemiology of chronic hepatitis B and C in Victoria,Australia: insights and impacts from enhanced surveillance

Objective : To assess the impact of an enhanced viral hepatitis surveillance program on data completeness and on epidemiological assessment of affected populations. Methods : Notified cases of non‐acute hepatitis B and C were analysed to determine demographic characteristics and risk factors during the period prior to July 2015–June 2016, and during enhanced surveillance of the period July 2016–June 2017, during which time doctors were contacted for information about new diagnoses. Results : During the enhanced period, completeness for country of birth and Indigenous status doubled for both hepatitis B and hepatitis C, from 18–37% to 48–65%. The incidence ratio of hepatitis C among Aboriginal and Torres Strait Islander people increased from eight‐fold to 11.4‐fold, and the proportion of hepatitis B cases reported as born in China and Vietnam relative to other countries increased. New data fields identified that 12% of hepatitis C diagnoses occurred in a correctional facility, and 2% of hepatitis B cases were healthcare workers. Conclusions : Improved data completeness highlighted the underlying epidemiology of chronic viral hepatitis, demonstrating the increased burden of infection among specific priority populations. Implications for public health : Enhanced surveillance provides greater insight into the epidemiology of chronic viral hepatitis, identifying groups at risk and opportunities for public health action.     

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness

In Italy in the 1980s the extent of viral hepatitis B infection was on average about 11,000 symptomatic cases of acute viral hepatitis (AVH) per year (19/100,000 inhabitants). The prevalence of HBsAg carriers in the general population was about 3% and in pregnant women 2.4%. 64,000 people were affected by chronic viral hepatitis (CVH) or cirrhosis (prevalence rate 112/100,000) and 3400 by hepatocellular carcinoma (HCC) (prevalence rate 5.9/100,000). To reduce these HBV related pathologies in the Italian population, universal vaccination of newborn babies, 12-year old adolescents and high risk groups was implemented in 1991. The annual cost of this immunization is about 57 million 544 thousand USD: direct costs: 41 million 34 thousand USD; indirect costs: 16 million 510 thousand USD. Concerning the vaccination impact on HBV endemicity in Italy, we found a significant reduction of acute viral hepatitis incidence (4.2/100,000 in 1996 versus 19/100,000 in the '80s) and HBsAg carrier prevalence (0.9% in 1997 versus 3% in the '80s). As for the assistance and social cost of acute viral hepatitis occurring from 1991 to 1996 (17,608 cases) it was 238 million 908 thousand USD, while the cost for the same pathology in the years from 1985 to 1990 (35,614 cases) was 483 million 216 thousand USD. Thus, the saving during the years of the vaccination was evaluated in 244 million 308 thousand USD. At the moment, we have no information about the reduction in chronic sequelae of HBV pathology as an effect of the vaccination, because the incidence of this pathology generally starts to appear after 15 years (in our case in 2006).     

南方某地区急性病毒性肝炎的分型与危险因素特点

目的：探讨部队与地方急性病毒性肝炎的型别与发病因素，为制定预防措施提供依据。方法：对驻广东、广西两所部队医院收治的急性病毒性肝炎101例进行了血清学分型与发病因素调查。结果：101例中部队病人42例，甲型肝炎（HA）52．38％，乙型肝炎（HB）40．48％，丙型肝炎（HC）7．14％。部队病人甲肝的发病因素主要为肝炎接触史（OR＝10．63），不洁饮食史（OR＝7．70），出差旅游史（OR＝5．71）。乙肝与丙肝主要与肝炎接触史（OR＝25．0，4．0）有关。地方病人59例，其中HA32．20％，HB40．68％，HC18．64％，混合感染8．47％。甲肝主要与肝炎接触史（OR＝5．95）、不洁饮食史（OR＝6．06）、出差旅游史（OR＝5．15）有关。乙肝主要与肝炎接触史（OR＝5．50），家庭成员既往肝炎史（OR＝4．20）有关。丙肝与肝炎接触史（OR＝8．33），输血史（OR＝3．75）有关。结论：病毒性肝炎的预防，部队人群应以甲肝为主，地方人群应以乙肝为主。     

Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017–2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10⁵ inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0–4 years olds (4 cases/10⁵ inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to cc11. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64–80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0–4 year olds, 25 of 43 (58%; 95% CI: 43–72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination.     

The surface antigen (HBsAg) and the e-antigen (HBeAg) in Somalian patients with acute viral hepatitis.

Serum samples from 55 Somalian patients with acute viral hepatitis were examined for the presence of the surface antigen (HBsAG) and the e-antigen (HBeAg) and the corresponding antibodies (anti-HBs and anti-e). No e-antigen was detected in patients with viral hepatitis or in controls (47 cases); anti-e was found in 23.6% of hepatitis cases, all of whom were HBsAg carriers, and in 10% of the controls. The HBsAg was found in 60% of cases with hepatitis and 34% of controls; the anti-HBs was detected in 18% of the patients with hepatitis, all except one of whom were negative for HBsAg; in the one exception the HBsAg and anti-HBs were present simultaneously; the anti-HBs was found in 44.6% of controls. The frequency of serological evidence of hepatitis B infection (HBV) based on the presence of antigen/antibody HBs was 78.2% among patients with acute viral hepatitis; only 30% of these patients showed evidence of anti-e antibody.     

Epidemiology and clinical outcome of hepatitis D virus infection in Turkey

The prevalence, the epidemiology, the clinical and biochemical characteristics of hepatitis delta virus (HDV) infection were studied in patients with HBsAg-positive acute hepatitis, in those with chronic liver disease, and in apparently healthy carriers in Turkey.Fifty-eight of the 242 carriers of HBsAg (23.9%) and 31 of the 237 (13.1%) patients with acute HBsAg-positive hepatitis had serological evidence of HDV infection. Eleven of these individuals were HBsAg carriers with acute HDV superinfection. The prevalence of HDV infection was significantly (p < 0.001) higher in patients with chronic liver disease (54/165; 32.7%) than in asymptomatic carriers of HBsAg (4/77; 5.2%). The highest prevalence (26/57; 45.6%) of HDV infection was found in patients at high risk of acquiring hepatitis virus infection (health care workers, hemodialysis patients, polytransfused patients) with chronic liver disease.Whereas the frequency of severe or fulminant hepatitis was similar in HBV infected patients (7.8%) and in HBV/HDV coinfected individuals (10%), the frequency of biphasic hepatitis was significantly (p < 0.005) higher in the latter patients (30%) than in those with classical hepatitis B (7.8%). Chronic evolution of the disease was observed in 3.9% of the patients with classical hepatitis B and in 5% of those who had evidence of simultaneous HBV/HDV infection. The 10 carriers of HBsAg who survived the acute HDV superinfection developed chronic delta hepatitis.These findings indicate that HDV is endemic in Turkey and that its prevalence is highest among chronic HBsAg-positive hepatitis patients, implicating HDV as a major cause of liver disease among urban Turkis.Corresponding author.     

两种重组乙型肝炎疫苗免疫效果对比研究

目的 客观地评价北京市现行不同乙型肝炎（乙肝）疫苗的免疫效果。方法 选择既往无乙肝疫苗接种史的大学生及出生时全程免疫过的儿童，检测血清HBsAg、抗-HBs及抗-HBc，全阴性者作为观察对象。入选大学生280人，按照0、1、6个月程序进行3针基础免疫，其中接种重组酿酒酵母乙肝疫苗（10μg、5μg、5μg）140人，重组汉逊酵母乙肝疫苗（10μg、10μg、10μg）140人。入选儿童98人进行1针加强免疫，其中酿酒酵母疫苗49人（5μg），汉逊酵母疫苗49人（10μg）。免疫后1个月采血检测抗-HBs。结果 大学生3针免疫后，抗-HBs有效阳转率（≥10mIU／ml）酿酒酵母疫苗低于汉逊酵母疫苗（93．5％，99．3％，P〈0．05），几何平均滴度（GMT）二：者差异无统计学意义（81．2mIU／ml，94．6mIu／ml，P〉0．05）。从男性看，接种酿酒酵母疫苗的抗体有效阳转率及GMT均低于汉逊酵母疫苗（85．7％，100．0％，P〈0．01）（56．6mIU／ml，98．6mIU／ml，P〈0．01），而对于女性，差异均无统计学意义（98．8％，98．5％，P〉0．05）（103．4mIU／ml，90．3mIU／ml，P〉0．05）。从同种疫苗不同性别看，接种酿酒酵母疫苗抗体有效阳转率及GMT男性均低于女性（85．7％，98．8％，P〈0．01）（56．6mIU／ml，103．4mIU／ml，P〈0．01），而汉逊酵母疫苗男女性差异均无统计学意义（100．0％，98．5％，P〉0．05）（98．6mIU／ml，90．3mIU／ml，P〉0．05）。出生时按程序免疫的儿童，其抗-HBs阳性率随年龄增长呈下降趋势（P〈0．01）。70例阴转者经1针加强免疫后，98．6％出现阳转，GMT显著提高到免疫前的15倍。阳转率及GMT2种疫苗差异无统计学意义（100．0％，97．4％，P〉0．05）（80．5mIU／ml，68．5mIU／ml，P〉0．05）。结论 乙肝疫苗的接种效果与疫苗种类及受种者性别均有关系。成人基础免疫，按目前常规使用剂量，男性接种汉逊酵母疫苗效果优于酿酒酵母疫苗，女性2种疫苗效果均好。儿童加强免疫，2种疫苗效果均较理想。重组疫苗初免后抗体阴转者的免疫记忆良好，新生儿完成重组乙肝疫苗全程免疫后至少6年之内无需加强。     

江西省2005～2012年急性乙型病毒性肝炎报告病例的流行病学特征分析

目的分析江西省2005-2012年急性乙型病毒性肝炎（乙肝）的流行病学特征,为预防控制乙肝提供参考。方法对中国疾病预防控制信息系统的疾病监测信息报告管理系统中,江西省2005-2012年急性乙肝报告病例的流行病学特征进行分析。结果江西省2005-2012年乙肝报告发病率波动在71.79/10万-81.33/10万。报告的乙肝病例中,急性乙肝占5.71%-12.46%,发病率从2005年的8.00/10万降至2012年的4.50/10万。〈15岁儿童急性乙肝年平均发病率低（1.73/10万）,2010-2012年均〈1/10万。不同性别间发病率差异有统计学意义（χ2=6816.90,P〈0.05）。急性乙肝病例农民最多（占52.25%）。萍乡市8年急性乙肝报告发病率〉10/10万,年最高报告发病率达31.72/10万。结论江西省急性乙肝报告发病率呈下降趋势,〈15岁儿童下降更为明显。